- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06295549
Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Phase I, Open-label Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LUCAR-G39P, a Dual-targeted Cell Preparation Targeting CD19/CD20, in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Huayuan Zhu, PhD,MD
- Phone Number: +86-13813810650
- Email: huayuan.zhu@hotmail.com
Study Locations
-
-
Jiangsu
-
Nanjin, Jiangsu, China, 210029
- Recruiting
- Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
-
Contact:
- Huayuan Zhu, PhD,MD
- Phone Number: 86 25 68306034
- Email: huayuan.zhu@hotmail.com
-
Contact:
- Yeqin Sha, MD
- Email: yeqinsha@njmu.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects have fully understood the possible risks and benefits of participating in this study, are willing to follow and able to complete all trial procedures, and have signed informed consent.
- Aged 18-75 years (inclusive).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically confirmed B-cell non-Hodgkin Lymphoma that expresses at least one of CD19/CD20.
- At least one evaluable tumor lesion according to Lugano 2014 criteria.
Response to prior therapy is consistent with one of the following:
- Primary refractory.
- Relapsed or refractory after 2 or more lines of therapy.
For LBCL, 3B FL. t-iNHL:
- Relapse within 12 months after first-line chemoimmunotherapy to achieve CR;
Progression or relapse within 12 months after autologous hematopoietic stem cell transplantation;
7. Life expectancy≥ 3 months 8. Clinical laboratory values meet screening visit criteria
Exclusion Criteria:
Subject eligible for this study must not meet any of the following criteria:
- Prior antitumor therapy with insufficient washout period ;
- Patients who received autologous CAR-T cell therapy (except CD19-targeted) or autologous gene therapy;
- Patients who received allogeneic hematopoietic stem cell transplantation or allogeneic therapy;
5. Patients who are positive for any index of hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), or human immunodeficiency virus antibody (HIV- Ab).
6. Known life-threatening allergies, hypersensitivity, or intolerance to LUCAR-G39P CAR-T cell or its excipients, including DMSO.
7. Pregnant or lactating women;
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental: LUCAR-G39P cells product
Each subject will be given a single-dose LUCAR-G39P cells infusion at each dose level.
|
LUCAR-G39P cells product Prior to infusion of the LUCAR-G39P, subjects will receive a conditioning premedication regimen consisting of cyclophosphamide and fludarabine
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence, severity and type of TEAEs
Time Frame: Through study completion , an average of 2 years after LUCAR-G39P infusion (Day 1)
|
An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
|
Through study completion , an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Pharmacokinetics in peripheral blood
Time Frame: ThTrough study completion , an average of 2 years after LUCAR-G39P infusion (Day 1)
|
CAR positive T cells and CAR transgene levels in peripheral blood after LUCAR-G39P infusion
|
ThTrough study completion , an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Pharmacokinetics in bone marrow
Time Frame: ThTrough study completion , an average of 2 years after LUCAR-G39P infusion (Day 1)
|
CAR positive T cells and CAR transgene levels in bone marrow after LUCAR-G39P infusion.
|
ThTrough study completion , an average of 2 years after LUCAR-G39P infusion (Day 1)
|
The recommended Phase II dose (RP2D) for this cell therapy
Time Frame: Within 30 days after LUCAR-G39P infusion
|
RP2D established through ATD+BOIN design and the DLTs occurring following CAR T-cell infusion
|
Within 30 days after LUCAR-G39P infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Objective Response Rate (ORR) is defined as the proportion of subjects who achieve CR or PR after treatment via LUCAR-G39P cell infusion
|
Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Progression-free survival (PFS)
Time Frame: Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
rogression Free Survival (PFS) is defined as the time from the date of first infusion of the LUCAR-G39P to the first documented disease progression (according to Lugano 2014) or death (due to any cause), whichever occurs first
|
Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Overall Survival (OS)
Time Frame: Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Overall Survival (OS) is defined as the time from the date of first infusion of LUCAR-G39P to death of the subject
|
Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Time to Response (TTR)
Time Frame: Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Time to Response (TTR) is defined as the time from the date of first infusion of LUCAR-G39P to the date of the first response evaluation of the subject who has met all criteria for CR or PR
|
Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Duration of Response (DoR)
Time Frame: Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Duration of Remission (DoR) is defined as the time from the first documentation of remission (CR or PR) to the first documented relapse evidence of the responders.
|
Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Immunogenicity assessment of LUCAR-G39P cells
Time Frame: Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
The incidence of Anti- LUCAR-G39P antibody in patients who received LUCAR-G39P cells infusion
|
Through study completion, an average of 2 years after LUCAR-G39P infusion (Day 1)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jianyong Li, PhD,MD, The First Affiliated Hospital with Nanjing Medical University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LB2304-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
-
Baylor College of MedicineThe Methodist Hospital Research Institute; Center for Cell and Gene Therapy...RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic LymphomaUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
Kite, A Gilead CompanyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma | Relapsed/Refractory Primary Mediastinal B Cell Lymphoma | Relapsed/Refractory Transformed Follicular Lymphoma | Relapsed/Refractory High-Grade B-Cell LymphomaUnited States
-
Kite, A Gilead CompanyRecruitingRelapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin LymphomaSpain, United States, Canada, Belgium, Poland, Czechia, Italy, France, Germany, Netherlands, Sweden
-
ADC Therapeutics S.A.RecruitingB-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin LymphomaUnited States, Spain, Italy, United Kingdom, Belgium, Czechia
-
CARsgen Therapeutics Co., Ltd.RenJi Hospital; First Affiliated Hospital of Zhejiang UniversityCompletedRefractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-cell Non-Hodgkin LymphomaChina
-
Affimed GmbHTerminatedRefractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin LymphomaUnited States, Czechia, Germany, Poland
-
BeiGeneRecruitingRefractory Chronic Lymphocytic Leukemia | Refractory Non-Hodgkin Lymphoma | Relapsed Follicular Lymphoma | Refractory Small Lymphocytic Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Diffuse Large B-cell Lymphoma | Transformed Non-Hodgkin Lymphoma | Relapsed... and other conditionsChina, Australia
-
Caribou Biosciences, Inc.Enrolling by invitationLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's LymphomaUnited States
-
920th Hospital of Joint Logistics Support Force...Gracell Biotechnology Shanghai Co., Ltd.; Kunming Hope of Health HospitalRecruitingRelapsed or Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed or Refractory B-cell Non-hodgkin LymphomaChina
Clinical Trials on LUCAR-G39P cells product
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityNanjing Legend Biotech Co.Not yet recruitingRelapsed/Refractory Multiple MyelomaChina
-
Tianjin Medical University Cancer Institute and...Nanjing Legend Biotech Co.Not yet recruitingB-Cell Non-Hodgkin Lymphoma-Recurrent | B-Cell Non-Hodgkin Lymphoma-RefractoryChina
-
The First Affiliated Hospital with Nanjing Medical...Nanjing Legend Biotechnology Co.,Ltd.; The First Affiliated Hospital of USTC...TerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic LymphomaChina
-
Peking University Cancer Hospital & InstituteRecruitingRelapsed/Refractory B-cell Non-Hodgkin LymphomaChina
-
Weijun FuNanjing Legend Biotech Co.RecruitingRelapsed/Refractory Multiple MyelomaChina
-
Weijun FuNanjing Legend Biotech Co.Active, not recruiting
-
Institute of Hematology & Blood Diseases Hospital...Nanjing Legend Biotech Co.TerminatedAcute Myeloid LeukemiaChina
-
Baylor College of MedicineNational Cancer Institute (NCI); Stand Up To Cancer; Center for Cell and Gene... and other collaboratorsRecruitingSarcoma | Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma | HER-2 Protein Overexpression | Undifferentiated SarcomaUnited States
-
JKastrupUniversity Medical Centre LjubljanaUnknownNon-ischemic Dilated CardiomyopathyDenmark
-
Qiu LuguiNanjing Legend Biotech Co.RecruitingB-cell Lymphoma Refractory | B-cell Lymphoma RecurrentChina